-An oxidant-antioxidant imbalance in the lung contributes to the development of chronic obstructive pulmonary disease (COPD) that is caused by a complex interaction of genetic and environmental risk factors. Nuclear erythroid 2-related factor 2 (NFE2L2 or NRF2) is a critical molecule in the lung's defense mechanism against oxidants. We investigated whether polymorphisms in the NFE2L2 pathway affected the rate of decline of lung function in smokers from the Lung Health Study (LHS)(n ϭ 547) and in a replication set, the Vlagtwedde-Vlaardingen cohort (n ϭ 533). We selected polymorphisms in NFE2L2 in genes that positively or negatively regulate NFE2L2 transcriptional activity and in genes that are regulated by NFE2L2. Polymorphisms in 11 genes were significantly associated with rate of lung function decline in the LHS. One of these polymorphisms, rs11085735 in the KEAP1 gene, was previously shown to be associated with the level of lung function in the Vlagtwedde-Vlaardingen cohort but not with decline of lung function. Of the 23 associated polymorphisms in the LHS, only rs634534 in the FOSL1 gene showed a significant association in the Vlagtwedde-Vlaardingen cohort with rate of lung function decline, but the direction of the association was not consistent with that in the LHS. In summary, despite finding several nominally significant polymorphisms in the LHS, none of these associations were replicated in the Vlagtwedde-Vlaardingen cohort, indicating lack of effect of polymorphisms in the NFE2L2 pathway on the rate of decline of lung function. genetic polymorphism; nuclear erythroid 2-related factor 2; forced expiratory volume in one second CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) is the result of a complex interaction of genetic and environmental risk factors (51) and is characterized by irreversible airflow obstruction that results from chronic inflammation and tissue remodeling. Although the main environmental risk factor for COPD is cigarette smoking, longitudinal studies show that only a minority of long-term cigarette smokers develops airflow limitation (15) , suggesting that additional environmental and/or genetic factors are important. Family and twin studies have demonstrated that genetic factors play a key role in the etiology of COPD (41, 49) . Furthermore, genome-wide association studies of lung function (19, 46, 50, 58, 63) , COPD (8, 47) , and emphysema (32) have identified several putative loci underlying these traits.
Several lines of evidence suggest that oxidant-antioxidant imbalance in the lung plays a major role in the pathogenesis of COPD. A measure of oxidative stress in the blood (thiobarbituric acid-reactive substances) was shown to correlate inversely with lung function in a population study (53) . In addition, reactive oxygen species released by circulating neutrophils play a role in the development of airflow limitation (38) . Furthermore, antioxidant nutrients have been associated with preservation of lung function (28, 42) .
Nuclear erythroid 2-related factor 2 (NFE2L2 or NRF2) is a basic leucine zipper transcription factor that upregulates multiple genes involved in antioxidant and detoxification pathways in response to exposure of the lungs to cigarette smoke (48) . Disruption of the Nfe2l2 gene in an emphysema-resistant mouse model resulted in an early-onset and severe cigarette smoke-induced emphysema, suggesting that NFE2L2 is a critical molecule in the lung's defense mechanism against oxidants (48) . Oxidative stress causes NFE2L2 to translocate to the nucleus following dissociation from its cytosolic inhibitor, KEAP1 (30) . We have shown (39) that the protein levels of NFE2L2 and DJ1 (PARK7), a stabilizer of NFE2L2 (9) , are decreased in the lungs of patients with COPD. These data indicate that NFE2L2 plays an important protective role against cigarette smoke-induced COPD.
A previous study (66) of four promoter polymorphisms in the NFE2L2 gene did not demonstrate any associations with COPD in the Japanese population. In contrast, an NFE2L2 polymorphism (rs2364723) in intron 2 of the gene was associated with level of lung function, although not with its rate of decline, in a European population (54) . Most recently, another variant (rs6726395) in intron 2 of the NFE2L2 gene was associated with rate of decline of lung function in the Japanese population and showed a significant interaction with smoking status (40) .
Based on these observations, we hypothesized that the rate of decline of lung function in smokers with mild to moderate airflow obstruction from the Lung Health Study (LHS) (1) would be influenced by polymorphisms in the NFE2L2 pathway. The LHS was a randomized trial of an antismoking intervention and bronchodilator treatment in volunteer smokers (1) . We selected polymorphisms in the NFE2L2 gene in genes that positively or negatively regulate the expression of NFE2L2 and in genes that are regulated by NFE2L2. We sought to determine whether these polymorphisms are associated with decline of lung function in smokers in the LHS and in a replication set, the Vlagtwedde-Vlaardingen cohort.
MATERIALS AND METHODS
Study participants. The analyses were performed in a nested case-control design that included participants from the LHS, a clinical trial sponsored by the National Heart, Lung, and Blood Institute (1). The LHS was conducted at 10 medical centers in North America, and a total of 5,887 smokers, aged 35-60 yr, with spirometric evidence of mild to moderate lung function impairment were recruited (1) . Lung function was assessed as forced expiratory volume in 1 s (FEV 1) % of predicted, i.e., FEV1 adjusted for age, height, sex, and race. Lung function measurements in the LHS were performed using standardized spirometry in accordance with the American Thoracic Society guidelines (14) , and the reference equations were those of Crapo and coworkers (10) based on Caucasian subjects of northern European descent in Salt Lake City.
Only participants who self-reported as non-Hispanic white were investigated in this study. Participants of other ethnic groups such as Hispanic white, African American, and Asian accounted for Ͻ5% of the total LHS cohort and were excluded to avoid potential problems due to population admixture.
Based on the rate of decline of lung function during a 5 yr follow-up period, of the 3,216 continuing smokers in this study, we selected non-Hispanic whites with a fast decline of FEV 1 (n ϭ 262) and with no decline of FEV 1 (n ϭ 285). Arbitrary cut-off points of FEV1% predicted/year decrease Ն3.0% and increase Ն0.4% were used for rapid decliners and nondecliners, respectively. The demographic characteristics of the participants are shown in Table 1 .
The Vlagtwedde-Vlaardingen cohort was utilized as an independent replication cohort (54) . This cohort contains 1,390 subjects with 8,159 FEV1 measurements completed during eight surveys who were prospectively followed for 25 yr with FEV1 measurements performed every 3 yr (following European Respiratory Society guidelines) (60) . Based on the rate of decline of lung function during this follow-up period, we selected smokers (smoking history Ͼ 5 pack-yr) with a fast decline of FEV1 (n ϭ 233) and with no decline of FEV1 (n ϭ 300). Arbitrary cut off points of FEV1% predicted/year decrease Ͼ0% and increase Ͼ7.4% were used for rapid decliners and nondecliners, respectively. The characteristics of these subjects are shown in Table 2 .
Informed consent was obtained from all participants, and this investigation received the approval of the relevant Research Ethics Boards.
Gene/polymorphism selection and genotyping. We selected genes involved in upregulation of NFE2L2 (APEX1, BRCA1, CARM1, CREBBP, DPP3, EP300, JUN, KAT2B, NCOA3, PARK7, PPARG, PRMT1, and SQSTM1) and downregulation of NFE2L2 (ATF3, BACH1, BACH2, FOS, FOSL1, GNA12, KEAP1, MAF, MAFK, and TP53). In addition, we selected genes known to be regulated by NFE2L2 (GPX2, GSR, and SRXN1). We also genotyped single nucleotide polymorphisms (SNPs) in three genes: NFE2L2; NFE2L1, a member of NFE2L family shown to act as a repressor of NFE2L2; and NFE2L3, a member of NFE2L family with high homology to NFE2L2. Finally, we selected a novel inflammatory gene (IRG1) as it was the most highly upregulated gene in the lungs of mice with a deletion of Nfe2l2 after lipopolysaccharide (LPS) treatment (59). Values are means Ϯ SD for continuous data. *Number of packs of cigarettes smoked per day/number of years smoking. †Change in lung function over the total period someone was in the study per year as % predicted FEV1 prebronchodilator. ‡Change in lung function over the total period someone was in the study per year as % predicted FEV1 postbronchodilator. §Lung function at the start of the Vlagtwedde/Vlaardingen as measured by FEV1(%) predicted prebronchodilator. ʈLung function at the start of the Vlagtwedde/Vlaardingen as measured by FEV1(%) predicted postbronchodilator. Genotyping of the LHS cohort was performed at the McGill University and Génome Québec Innovation Centre (Montreal, Qué-bec, Canada) using Illumina GoldenGate assays. Whole genome amplified DNA was used as a template for the assays. We included polymorphisms in the IL10 and IL10RA genes as quality controls to assess the whole genome amplification, since these polymorphisms have previously been genotyped in the LHS using genomic DNA as a template (22) . The genotypes generated from whole genome amplified samples showed good concordance rates (98.1-99.6%) compared with those from genomic samples (data from 9 SNPs in the IL10 and IL10RA genes).
Of the 619 LHS samples that were genotyped, samples with call rates Ͻ95% (n ϭ 40) were removed from the analysis. Analyses were further limited to non-Hispanic whites (n ϭ 547) of whom 262 were rapid decliners and 285 were nondecliners (Table 1) . Of the 349 SNPs that were chosen for genotyping, SNPs with call rates Ͻ90% (n ϭ 37), SNPs that were monomorphic (n ϭ 6), and SNPs that were not in Hardy-Weinberg equilibrium (n ϭ 8) were not analyzed. Thus, 298 polymorphisms were included in the analyses.
Genotyping of the Vlagtwedde-Vlaardingen cohort was performed at K-Biosciences (Hoddesdon, UK) using their patent-protected KASPar technology. SNPs were chosen for genotyping in this cohort if they were associated with rate of decline of lung function in the LHS (P Ͻ 0.05). However, SNP rs6125042 (in NCOA3) was excluded from the analysis due to a low call rate (71%) and lack of Hardy-Weinberg equilibrium (P ϭ 0.02).
Statistical analysis. For the LHS cohort, Hardy-Weinberg equilibrium tests were performed using the Arlequin population genetics package (52) , and linkage disequilibrium (LD) estimation was done using the CubeX, cubic exact solutions program (16) . All tests of association were performed under an additive genetic model. The outcome was a dichotomous variable i.e., fast vs. nondecline in lung function (FEV 1% predicted). The SimHap software (5) was used to perform the multivariate logistic regressions adjusting for confounding factors, i.e., age, sex, pack-years of smoking, and recruitment center.
A Bonferroni correction for the total number of comparisons (n ϭ 298) conducted in the LHS cohort may be overly conservative due to LD between the SNPs. Therefore, we used the SNP Spectral Decomposition (SNP SpD) approach to estimate the effective number of independent marker loci (M eff) (45) . With use of the SNP SpD approach and the estimate of Meff provided by Li and Ji (36), the Meff for this experiment was 203.5, and the experiment-wide significance threshold required to keep the type I error rate at 5% was 0.000252.
In the analysis of the LHS, several of the polymorphisms had small numbers in one or more of the cells, and therefore the conventional 2 -test may not be valid. To address this issue, the P values were reassessed by the permutation procedure implemented in UNPHASED (12), using 10,000 random permutations for each SNP.
For the Vlagtwedde-Vlaardingen cohort, an additive genetic model was used to test the association of polymorphisms with the dichotomous outcome of fast vs. nondecline in lung function (FEV 1% predicted). The SPSS (version 16) software was used to perform the analyses adjusting for sex and pack-years. HardyWeinberg equilibrium tests were performed with Haploview (version 4.1) (2).
RESULTS

LHS cohort.
The most significant associations of the candidate polymorphisms with rate of decline of lung function in the LHS group under the additive model are shown in Table 3 . We found previously unreported associations of polymorphisms in 11 genes in the NFE2L2 pathway. The odds ratios for polymorphisms in these genes ranged from 0.44 to 0.76 for protective alleles and from 1.31 to 2.04 for risk alleles. The most significant associations were in the IRG1, NCOA3, and KEAP1 genes. Several of these associations were also nominally significant (P Ͻ 0.05) when analyzed by the permutation procedure implemented in UNPHASED (12) ( Table 3) .
The majority of polymorphisms (14/23) associated with rate of decline of lung function were tagging SNPs. None of these SNPs were of obvious functional significance although a synonymous polymorphism in the EP300 gene (rs20552) was in a highly conserved region.
Although 23 polymorphisms showed nominal association with rate of decline of lung function (P Ͻ 0.05) under the additive model (Table 3) , none of these associations remained significant after correction using the effective number of independent marker loci. The estimated effective number of independent SNPs (n ϭ 203) is lower than the actual number (n ϭ 298) due to the moderate level of LD between the polymorphisms. For example, the LD between the SNPs associated with lung function is shown for the LHS data in Fig. 1 .
Vlagtwedde-Vlaardingen cohort. We attempted to replicate the associations observed in the LHS cohort using the Vlagtwedde-Vlaardingen cohort. Of the 23 associated SNPs, one polymorphism in KEAP1 (rs11085735) was previously genotyped in this cohort (54) and another in NFE2L2 (rs10183914) was in LD (r 2 ϭ 0.96) with a previously geno- The odds ratios are for a rapid rate of decline and the reference is the wild-type homozygote genotype. SNP, single nucleotide polymorphism. *Likelihood ratio 2 -test. †P value using 10,000 random permutations. ‡Association under an additive genetic model adjusted for age, sex, pack-years of smoking, and recruitment center.
typed SNP (54) . The LD between the SNPs in this cohort is shown in Fig. 2 . All the polymorphisms were in HardyWeinberg equilibrium (P Ն 0.12). Associations of the SNPs with rate of decline of lung function are shown in Table 4 . Only SNP rs634534 in the FOSL1 gene showed a significant association in the Vlagtwedde-Vlaardingen cohort (P ϭ 0.016), but the direction of the association was reversed compared with the LHS.
DISCUSSION
We investigated whether polymorphisms in NFE2L2 pathway genes were associated with the rate of decline of lung function in the LHS cohort. NFE2L2 is a master regulator of the antioxidant and detoxification pathways, and therefore the genes that we investigated are excellent candidates for COPD susceptibility loci. The four genes that showed the most significant associations in the LHS were IRG1, NCOA3, KEAP1, and BACH2. All these associations with rate of decline of lung function are novel, although we previously demonstrated that the polymorphism in the KEAP1 gene (rs11085735) was associated with cross-sectionally determined level of lung function (54) .
Irg1 was most highly upregulated in the lungs of Nfe2l2 Ϫ/Ϫ mice following LPS treatment (59) . Irg1 was transcriptionally upregulated in LPS-stimulated macrophages (3, 34) and showed marked differences in expression in Nfe2l2 ϩ/ϩ and Nfe2l2 Ϫ/Ϫ mice after administration of LPS and exposure to cigarette smoke (59) . Four polymorphisms in the IRG1 gene showed significant associations with lung function decline in the LHS cohort. Three of the polymorphisms were in strong LD with each other (r 2 ϭ 0.68 -0.82), but the other SNP (rs831172) showed an independent association.
Four SNPs in the NCOA3 gene were nominally associated with rapid decline of lung function. There was strong LD (r 2 ϭ 0.60) between two of these variants (rs3092794 and rs2143491), but the remaining two SNPs were likely independent associations. NCOA3 is a member of the p160/steroid receptor coactivator family. NCOA3 associates with the transcription factor CREB binding protein and has histone acetyltransferase activity (6) . NCOA3 regulates several transcription factors (17, 35, 62, 64) and acts as a positive regulator of NFE2L2 expression (37) .
KEAP1 is a key inhibitor of NFE2L2 (30, 61) . NFE2L2 is rapidly ubiquitinated and degraded by the proteasome under basal conditions, and this degradation is promoted by KEAP1. However, binding of KEAP1 to compounds that activate NFE2L2 (oxidants and electrophiles) through its cysteine residues leads to the release and nuclear translocation of NFE2L2 and subsequent induction of NFE2L2-regulated genes (11, 13, 25, 31) . We found that a polymorphism in the KEAP1 gene (rs11085735) was associated with rate of decline of lung function in the LHS in the present study and previously with level of lung function in the Vlagtwedde-Vlaardingen cohort (54) . Taken together with the functional role of the protein, these data suggest a role for KEAP1 as a novel candidate gene for COPD. 
Continued
There were four SNPs in the BACH2 gene that were associated with decline in lung function. Interestingly, there was no strong LD between any of these polymorphisms, suggesting that the associations were independent. BACH2 is a transcription factor that plays a key role in the regulation of nucleic acid-triggered antiviral responses in human cells (26) and is highly expressed in B cells (43) . BACH2 acts as a functional antagonist of NFE2L2 (27) .
We were unable to replicate the associations observed in the LHS cohort using the Vlagtwedde-Vlaardingen cohort. Of the 23 associated SNPs, only rs634534 in the FOSL1 gene showed a significant association in the VlagtweddeVlaardingen cohort, but the direction of the association was not consistent with that in the LHS. SNP rs11085735 in the KEAP1 gene showed significant association in the Vlagtwedde-Vlaardingen cohort as previously reported (54) , but this association was with the level lung function and not with decline of FEV 1 .
The lack of replication may be related to the differences in recruitment between the two studies. The LHS selected mild to moderate COPD patients and the VlagtweddeVlaardingen cohort was from the general population. It is possible that the genetic factors that influence lung function decline in COPD patients could be different than those in the general population. In addition, despite the moderate sample sizes of both of the cohorts lack of replication may be due low power to detect risk alleles of small effect. To address this aspect of the study we have performed power analyses for both cohorts (Fig. 3) . We have good power to detect associations with odds ratios Ն2.0 and reasonable power for common variants with odds ratios Ն1.75 in the LHS. We had higher power to detect associations in the Vlagtwedde-Vlaardingen cohort due to the lower number of comparisons. Nevertheless, odds ratios of genetic associations with COPD are often Ͻ1.5, and therefore lack of power needs to be considered when interpreting these data.
Although we did not find replication of the NFE2L2 pathway genes studied in our cohorts, there is evidence of the role of this pathway in the development of COPD. SNPs in classical NFE2L2 targets such as glutathione S-transferase (GST) genes, NAD(P)H quinone oxidoreductase (NQO1), glutamate-cysteine ligase catalytic subunit (GCLC), and heme oxygenase-1 (HMOX1) have previously been shown to be associated with COPD (7, 18, 20, 21, 29, 33, 44, 55, 56, 65, 69) . In contrast, other studies failed to find association of these genes with COPD-related phenotypes (23, 24, 57, 67, 68) .
In summary, despite finding several nominally significant polymorphisms in the LHS, none of these associations were replicated in the Vlagtwedde-Vlaardingen cohort, indicating lack of effect of polymorphisms in the NFE2L2 pathway on the rate of decline of lung function. Alternatively these polymorphisms may have an effect, but our study is underpowered to detect these effects. Combining these data in subsequent meta analyses may be fruitful to more rigorously test their effects. The odds ratios are for a rapid rate of decline, and the reference is the wild-type homozygote genotype. †In almost complete linkage disequilibrium (r 2 ϭ 0.964) with SNP rs10183914 according to HapMap.
